Patient-reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 Countries.

Clinical trials Kidney cancer Patient-reported experience Psychosocial support Shared decision-making

Journal

European urology open science
ISSN: 2666-1683
Titre abrégé: Eur Urol Open Sci
Pays: Netherlands
ID NLM: 101771568

Informations de publication

Date de publication:
Mar 2022
Historique:
accepted: 09 12 2021
entrez: 4 3 2022
pubmed: 5 3 2022
medline: 5 3 2022
Statut: epublish

Résumé

The International Kidney Cancer Coalition (IKCC) is a federation of 46 affiliated patient organisations representing 1.2 million patients worldwide that is committed to reducing the global burden of kidney cancer. A large-scale global survey of patients with renal cell carcinoma (RCC) to capture real-world experiences has never been undertaken. The 35-question survey was designed to identify geographic variations in patient education, experience, awareness, access to care, best practices, quality of life, and unmet psychosocial needs. A total of 1983 responses were recorded from 43 countries in 14 languages. Analysis revealed key findings. (1) At diagnosis, 43% of all respondents had no understanding of their RCC subtype. (2) Shared decision-making remains aspirational: globally, 29% of all patients reported no involvement in their treatment decision, responding "My doctor decided for me". (3) While 96% of respondents reported psychosocial impacts, surprisingly, only 50% disclosed them to their health care team. (4) Lastly, 70% of patients were not asked to participate in a clinical trial, although 90% indicated they would be interested. The survey reflects patient perspectives from diverse clinical scenarios in which different treatment options are available. The data point to actionable deficits in the fields of clinical trials, psychosocial support, and shared decision-making. In this brief report, we highlight the key results from the first large-scale global survey of patients with kidney cancer to capture real-world experiences. This survey reflects patient perspectives from diverse clinical scenarios in which different treatment options are available. We conclude that there is a need for improvement in the fields of clinical trials, psychosocial support, and shared decision-making.

Identifiants

pubmed: 35243386
doi: 10.1016/j.euros.2021.12.003
pii: S2666-1683(21)03393-0
pmc: PMC8883191
doi:

Types de publication

Journal Article

Langues

eng

Pagination

3-6

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021 Published by Elsevier B.V. on behalf of European Association of Urology.

Références

Cancer. 2022 Feb 1;128(3):479-486
pubmed: 34609761
Sci Rep. 2021 Jan 14;11(1):1479
pubmed: 33446693
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
BJU Int. 2019 Feb;123(2):208-209
pubmed: 30253048
JCO Oncol Pract. 2020 Nov;16(11):e1264-e1271
pubmed: 32955409
World J Urol. 2021 Jul;39(7):2559-2565
pubmed: 33090258

Auteurs

Rachel Giles (R)

International Kidney Cancer Coalition, Amsterdam-Duivendrecht, The Netherlands.

Deborah Maskens (D)

International Kidney Cancer Coalition, Amsterdam-Duivendrecht, The Netherlands.
Kidney Cancer Canada, Mississauga, ON, Canada.

Robert Bick (R)

Kidney Cancer Canada, Mississauga, ON, Canada.

Robin Martinez (R)

Smart Patients Inc., Mountain View, CA, USA.

Malcolm Packer (M)

Kidney Cancer UK, Cambridge, UK.

Daniel Heng (D)

Tom Baker Cancer Centre, University of Calgary, Calgary, Canada.

James Larkin (J)

Royal Marsden NHS Foundation Trust, London, UK.

Axel Bex (A)

Royal Free London NHS Foundation Trust, London, UK.

Michael Jewett (M)

Princess Margaret Hospital Cancer Centre and University of Toronto, Toronto, Canada.

Eric Jonasch (E)

MD Anderson Cancer Center, Houston, TX, USA.

Sara MacLennan (S)

Academic Urology Unit, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.

Classifications MeSH